Methylene Blue — Redox / Mitochondrial Agent

Methylene blue is an old synthetic dye with a real pharmacological life: an FDA-approved treatment for methemoglobinemia that has lately become a popular off-label longevity and nootropic supplement. It is filed in the Pharmacologic / Redox Agents family, because its dominant action is redox and mitochondrial electron transport — chemistry, not energy medicine. It also has a photodynamic-therapy facet that cross-references the Photonic family, but to be clear up front: methylene blue is not photobiomodulation.

The real substrate — redox and mitochondrial electron transport

The keep half is genuine pharmacology. Methylene blue is a redox-active molecule: it participates in electron cycling and can support mitochondrial electron-transport chemistry, and at approved doses it has a defined clinical use in methemoglobinemia. Separately, it carries a photodynamic-therapy (PDT) facet — as a photosensitiser it can generate reactive oxygen when illuminated. That PDT facet is why the entry cross-refers to the Photonic family, but it is a different light-chemistry from photobiomodulation's cytochrome-c-oxidase mechanism. The substrate to keep is the redox / mitochondrial pharmacology and the approved methemoglobinemia use.

Claim vs evidence — why grade B/C

This is the core, and it splits cleanly. For its approved use, methylene blue rests on real pharmacology — grade B. The off-label longevity, nootropic, anti-aging, and “mitochondrial supplement” uses are a different story: speculative, graded C. The FDA label (PROVAYBLUE, DailyMed) confirms the single approved indication — acquired methemoglobinemia; the longevity and nootropic uses are off-label and speculative, which fits the grade-C reading. The honest failure mode is the leap from “real redox drug with an approved indication” to “proven anti-aging compound,” often dressed in “frequency” or “cellular energy” branding. The approved-use evidence does not carry the supplement claims, and the grade B/C is precisely a refusal to average the two together.

Why this tier — and the dual indication-vs-off-label split

Methylene blue carries a dual badge because tier attaches to the claim, not the molecule. For methemoglobinemia — the FDA-approved indication — it is Evidence-supported. For longevity, nootropic, anti-aging, and “mitochondrial” supplement use it is Insufficient-evidence / under study. The three axes stay separate: plausibility is reasonable for the known uses but only speculative for longevity; evidence grade is B for the approved use and C off-label; and tier therefore differs by indication. A plausible redox mechanism does not promote the speculative longevity claim into the supported tier.

Regulatory by jurisdiction

The regulatory split tracks the evidence split. In the US, methylene blue is a prescription drug for its approved uses (methemoglobinemia), while supplement-channel use varies. In the EU it is likewise prescription for approved uses. For Russia, China's NMPA, and Australia's TGA, the source does not specify a status. The standard caveat applies with extra force given the supplement market: the prescription approval attests to a specific indication, not to the off-label longevity or nootropic claims sold through the supplement channel.

Lineage — an old drug, repurposed

Methylene blue is an old drug — redox, mitochondrial, photodynamic — rather than a product of the “frequency” lineage on the lineage page. Its only kinship with that fringe is the marketing overlay: the “frequency” and anti-aging branding now attached to a genuine pharmacological agent. Note again that its PDT facet is cross-referenced to the Photonic family, not folded into photobiomodulation — the dominant axis here is redox pharmacology.

Keep vs set aside

Keep: the real pharmacology — redox / mitochondrial electron transport and the approved methemoglobinemia use. Set aside: the “frequency” / anti-aging branding, which is misleading, and the off-label longevity and nootropic uses, which are speculative rather than established. The discipline is to keep the approved indication and the genuine chemistry while declining to let either underwrite the supplement-market claims.